Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Other Non-Current Assets (2016 - 2025)

Protalix BioTherapeutics has reported Other Non-Current Assets over the past 16 years, most recently at $578000.0 for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $578000.0 for Q4 2025, up 25.11% from a year ago — trailing twelve months through Dec 2025 was $578000.0 (up 25.11% YoY), and the annual figure for FY2025 was $578000.0, up 25.11%.
  • Other Non-Current Assets for Q4 2025 was $578000.0 at Protalix BioTherapeutics, up from $549000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Assets for PLX hit a ceiling of $2.1 million in Q4 2021 and a floor of $459000.0 in Q1 2025.
  • Median Other Non-Current Assets over the past 5 years was $1.3 million (2023), compared with a mean of $1.1 million.
  • Biggest five-year swings in Other Non-Current Assets: tumbled 58.33% in 2023 and later grew 25.11% in 2025.
  • Protalix BioTherapeutics' Other Non-Current Assets stood at $2.1 million in 2021, then crashed by 39.0% to $1.3 million in 2022, then plummeted by 58.33% to $528000.0 in 2023, then fell by 12.5% to $462000.0 in 2024, then increased by 25.11% to $578000.0 in 2025.
  • The last three reported values for Other Non-Current Assets were $578000.0 (Q4 2025), $549000.0 (Q3 2025), and $520000.0 (Q2 2025) per Business Quant data.